The effects of human GH and its lipolytic fragment (AOD9604) on body weight and adiposity
Skip to main content search 0 Menu Home About Success Stories Video Testimonials Franchisee Opportunities Ideal Franchisee Owner Ask Our Franchisees Shop All Products Bundles Womens Health & Beauty Protein Powder & Bars Supplements Vitamins Drink Mixes Accessories Studios Blog Contact twitter facebook linkedin youtube google-plus instagram tiktok search 0 was successfully added to your cart
intracellular half-life is prolonged because of lysosomal release and cytosolic resequestration, creating a depot effect that supports monthly maintenance dosing for chronic deficiencies
By inhibiting NNMT, 5-Amino-1MQ has been observed in models to elevate NAD+, activate downstream metabolic regulators, and support pathways that encourage higher energy expenditure and reduced adiposity
Consult the Safety Data Sheet for full handling guidance
Key metabolic effects include: Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat Increased fat oxidation and energy expenditure in multiple species models No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone Independence from IGF-1 Signaling A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation: No measurable changes in serum IGF-1 levels in human clinical trials Absence of growth-promoting effects on tissues No impact on blood glucose regulation or insulin resistance Avoidance of typical growth hormone side effects including edema and tissue overgrowth Metabolic Pathway Modulation Research indicates AOD-9604 influences energy metabolism through multiple mechanisms: Increased whole-body fat oxidation rates in animal models Enhanced metabolic rate without stimulant-like effects Potential modulation of uncoupling proteins in adipose tissue Effects on lipid metabolism that persist beyond plasma clearance Critical Mechanistic Gap: Despite extensive research, the primary receptor target for AOD-9604 remains unidentified
